Summary:
In patients with diabetic peripheral neuropathy (DPN), once-daily prolonged-release (PR) pregabalin significantly improved pain management compared to placebo and was comparable to immediate-release (IR) pregabalin, though it was associated with common side effects like dizziness and somnolence.
| PICO | Description |
|---|---|
| Population | Patients with diabetic peripheral neuropathy experiencing moderate to severe pain. |
| Intervention | Once-daily prolonged-release pregabalin (150–600 mg/day). |
| Comparison | Placebo and immediate-release pregabalin (thrice-daily doses of 150–600 mg/day). |
| Outcome | Pregabalin PR had comparable efficacy to pregabalin IR in managing pain and significantly improved outcomes compared to placebo. Common side effects included dizziness and somnolence. |
Source: Shilpi Dhawan, et al. “Efficacy and Safety of Once-Daily Prolonged-Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Active, and Placebo-Controlled Trial.” Read article here.
